HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm
Hims & Hers Health, Inc. Class A (HIMS)
Company Research
Source: GlobeNewswire
LOS ANGELES, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. (“Hims & Hers” or “the Company”) (NYSE: HIMS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Hims & Hers is the subject of a statement by the FDA in which the agency announced "its intent to take decisive steps to restrict GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs that are being mass-marketed by companies — including Hims & Hers and other compounding pharmacies — as similar alternatives to FDA-approved drugs." The Company is also the subject of a lawsuit filed by Novo Nordisk seeking to bar it from selling compounded weight loss drugs. Based on this news, shares of Hims & Hers
Show less
Read more
Impact Snapshot
Event Time:
HIMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HIMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HIMS alerts
High impacting Hims & Hers Health, Inc. Class A news events
Weekly update
A roundup of the hottest topics
HIMS
News
- Hims & Hers Health (HIMS) Is Down 29.2% After Semaglutide Lawsuit And DOJ Referral - Has The Bull Case Changed? [Yahoo! Finance]Yahoo! Finance
- Hedge funds bet big against Hims & Hers Health before Wegovy showdown, Hazeltree data shows [Yahoo! Finance Canada]Yahoo! Finance Canada
- Hedge funds bet big against Hims & Hers Health before Wegovy showdown, Hazeltree data shows [Yahoo! Finance]Yahoo! Finance
- Mixed options sentiment in Hims and Hers Health with shares down 2.18% [Yahoo! Finance]Yahoo! Finance
- Hims & Hers: Does Big Pharma Always Win? (Rating Downgrade) [Seeking Alpha]Seeking Alpha
HIMS
Earnings
- 11/3/25 - Miss
HIMS
Sec Filings
- 2/13/26 - Form SCHEDULE
- 2/4/26 - Form 4
- 1/21/26 - Form 4
- HIMS's page on the SEC website